Bold steps for
a bright future
2021 - A year of investments and transformation
2021 was an eventful year for LEO Pharma as we focused on implementing our 2030 Strategy. We took bold and historic steps towards a bright future within medical dermatology. A future in which we create hope by advancing the standard of care for the benefit of people with skin conditions, their families and society.
Revenue for 2021 ended at DKK 9,957 million. Excluding the products divested in 2020 revenue grew by 5%. Operating loss before interest and tax (EBIT) ended at DKK 4,156 million. This reflects a significant loss that was related in particular to the high planned investment in the launch of tralokinumab, as well as impairment of intellectual property and continued high investment in R&D activities.
The future looks promising for LEO Pharma. In 2021, we took bold steps in pursuit of our 2030 Strategy. We will continue this work diligently in the coming years, in order to position LEO Pharma as a global leader in medical dermatology.
For more information about our 2021 performance, read our Annual Report 2021 and Sustainability Report 2021. For previous years’ reports, please see Archive below.
Sustainability / CSR reports
From 2018-2020, we did not publish a separate Sustainability or CSR report. For these years, our CSR reporting was incorporated into our Annual Report. Find our previous CSR reports here:
CSR Report 2017 (PDF)
CSR Report 2016 (PDF)
CSR Report 2015 (PDF)
CSR Report 2014 (PDF)
Environmental performance reports
Please find our Environmental Performance Reports covering environmental data from our manufacturing sites at country level here:
Corporate Environmental Performance Report 2020 (PDF)
Corporate Environmental Performance Report 2019 (PDF)
Corporate Environmental Performance Report 2018 (PDF)
Corporate Environmental Performance Report 2017 (PDF)
Corporate Environmental Performance Report 2016 (PDF)
Corporate EHSE Report 2015 (PDF)
Corporate EHSE Report 2014 (PDF)
Corporate EHSE Report 2013 (PDF)